Weekly Digest – March 2025 Weekly Digest – March 2025 27 Mar 2025: TIVDAK (Tisotumab vedotin) approved by Japan Ministry of Health, Labour and Welfare for the treatment of advanced or recurrent Cervical cancer that has progressed on or after […]
Weekly Digest – March 2025 Weekly Digest – March 2025 24 Mar 2025: Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer Innovent Biologics has successfully dosed the first participant in […]
Weekly Digest – March 2025 Weekly Digest – March 2025 21 Mar 2025: MacroGenics pulls plug on Vobra duo ADC after seeing phase 2 prostate cancer data MacroGenics decided to halt the development of Vobramitamab duocarmazine (Vobra duo) after reviewing […]
Weekly Digest – March 2025 Weekly Digest – March 2025 24 Mar 2025: AbbVie lawsuit alleges that partner Genmab “misappropriated” trade secrets AbbVie has sued Genmab, alleging that the company misappropriated trade secrets related to antibody-drug conjugate (ADC) technology, which […]
Weekly Digest – March 2025 Weekly Digest – March 2025 21 Mar 2025: Eisai’s abandoned Enhertu challenger set to live on at BlissBio Eisai decided not to exercise its option to acquire BB-1701, a HER2-directed antibody-drug conjugate (ADC) from Bliss […]
Weekly Digest – March 2025 Weekly Digest – March 2025 26 Mar 2025: GV20 Therapeutics announces collaboration agreement with Mitsubishi Tanabe Pharma Corporation to develop novel antibody-drug conjugates GV20 Therapeutics and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered a strategic […]
